{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000797","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.350645+00:00","generated_at":"2026-06-15T07:32:14.464143+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Teva Q1 revenue $3.7B flat YoY; non-GAAP EPS $0.40 down from $0.55; reaffirms FY 2023 outlook","bullets":["Revenues $3,661M flat YoY (up 4% local currency); GAAP loss per share ($0.18) improved from ($0.86).","Non-GAAP diluted EPS $0.40 vs $0.55 YoY; adjusted EBITDA $899M, down 21% from $1,135M.","Non-GAAP gross margin 49.1%, down from 54.2% due to inflationary pressures and unfavorable mix.","AUSTEDO grew 10% YoY and AJOVY grew 35% (local currency); UZEDY approved for schizophrenia.","Full-year 2023 outlook reaffirmed: revenue $14.8-15.4B, non-GAAP EPS $2.25-2.55, free cash flow $1.7-2.1B."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000797","json":"https://secwatch.observer/filing/0001157523-23-000797.json","markdown":"https://secwatch.observer/filing/0001157523-23-000797.md","text":"https://secwatch.observer/filing/0001157523-23-000797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752323000797/0001157523-23-000797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752323000797/a53397230.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:32:14.464143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50fd49644bdbd1ff6a80b307c709cec5dd9a0a95","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended March 31, 2023 results: revenue $3,661 million, EPS GAAP loss per share of $0.18; Non-GAAP diluted EPS of $0.40. Guidance reaffirmed.","evidence_excerpt":"where we will make decisive choices and focus our resources to drive growth and innovation.\" First Quarter 2023 Consolidated Results Revenues in the first quarter of 2023 were $3,661 million, flat compared to the first quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from generic products in our Europe and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000115752323000797/0001157523-23-000797-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$3,661 million"},{"label":"EPS","value":"GAAP loss per share of $0.18; Non-GAAP diluted EPS of $0.40"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}